Market Cap 227.67M
Revenue (ttm) 43.26M
Net Income (ttm) -45.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -104.74%
Debt to Equity Ratio 0.00
Volume 159,900
Avg Vol 315,950
Day's Range N/A - N/A
Shares Out 47.23M
Stochastic %K 9%
Beta 1.32
Analysts Strong Sell
Price Target $33.80

Company Profile

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3457 6900
Address:
72 Hammersmith Road, London, United Kingdom
LIGator
LIGator Jan. 27 at 4:59 PM
$GLSI trimmed a few shares that I bought last week at 23.81 so I could add more $SLN at $5.26. 2026 will be the year for both.
0 · Reply
LIGator
LIGator Jan. 26 at 2:56 PM
$SLN unbelievable. Up 6% in Europe, up 6% premarket here only to go negative
1 · Reply
LIGator
LIGator Jan. 26 at 2:00 PM
$SLN https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-silence-therapeutics-stock-at-75-93CH-4462756
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 26 at 11:30 AM
$SLN RSI: 41.89, MACD: -0.1993 Vol: 0.32, MA20: 5.82, MA50: 6.25 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
turp
turp Jan. 22 at 8:27 PM
$SLN Cmon can we get some buyout news or partnership for zerlasiran. They need to get working on that. Sitting on phase 3 forever
0 · Reply
hitmongreen
hitmongreen Jan. 22 at 4:33 PM
$SLN lets ride here!
0 · Reply
WeAllFallDown
WeAllFallDown Jan. 21 at 7:38 PM
$SLN Anyone else find that the board actions were a bit strange, someone care to explain?
2 · Reply
LIGator
LIGator Jan. 20 at 12:59 PM
$SLN pretty heavy premarket activity today. Let’s see if we can get a little bounce.
0 · Reply
hitmongreen
hitmongreen Jan. 16 at 6:56 PM
$SLN someone say something smart!
1 · Reply
Market_Luther_Kang
Market_Luther_Kang Jan. 14 at 10:57 AM
$SLN The "digital smoke" is getting thick. 🕵️‍♂️ Just audited the IR server (q4cdn) and we’ve got a massive technical shift. The /2026/ directory just flipped from a 403 Forbidden to a 302 Redirect. Why this matters: A 302 redirect means the content is STAGED and LIVE on the backend, but they are temporarily routing traffic away until the exact "Go-Live" timestamp. Combine that with the new http://Schema.org "@type: Event" tags that just hit the header code for Jan 14th, and you realize this isn't just a slide deck update. You don't "embargo" a routine presentation. You embargo a Merger Announcement. Don't forget the Jan 6th Form 4s—the entire board (Ross, Hellums, etc.) converted their options to common shares 8 days ago. They cleaned the cap table for a reason. I think we see an announcement soon.
0 · Reply
Latest News on SLN
Silence Therapeutics Announces Leadership Changes

Dec 15, 2025, 8:13 AM EST - 6 weeks ago

Silence Therapeutics Announces Leadership Changes


Silence Therapeutics: Divesiran Targets High-Burden PV

Nov 18, 2025, 6:03 AM EST - 2 months ago

Silence Therapeutics: Divesiran Targets High-Burden PV


Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 11:59 AM EST - 1 year ago

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript


Top 3 Health Care Stocks That May Explode In Q4

Dec 18, 2024, 7:46 AM EST - 1 year ago

Top 3 Health Care Stocks That May Explode In Q4

OLMA


Top 3 Health Care Stocks You'll Regret Missing In Q4

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

AMRN TERN


Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 10:01 AM EDT - 2 years ago

Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript


Silence Therapeutics Reports Second Quarter 2023 Results

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Reports Second Quarter 2023 Results


LIGator
LIGator Jan. 27 at 4:59 PM
$GLSI trimmed a few shares that I bought last week at 23.81 so I could add more $SLN at $5.26. 2026 will be the year for both.
0 · Reply
LIGator
LIGator Jan. 26 at 2:56 PM
$SLN unbelievable. Up 6% in Europe, up 6% premarket here only to go negative
1 · Reply
LIGator
LIGator Jan. 26 at 2:00 PM
$SLN https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-silence-therapeutics-stock-at-75-93CH-4462756
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 26 at 11:30 AM
$SLN RSI: 41.89, MACD: -0.1993 Vol: 0.32, MA20: 5.82, MA50: 6.25 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
turp
turp Jan. 22 at 8:27 PM
$SLN Cmon can we get some buyout news or partnership for zerlasiran. They need to get working on that. Sitting on phase 3 forever
0 · Reply
hitmongreen
hitmongreen Jan. 22 at 4:33 PM
$SLN lets ride here!
0 · Reply
WeAllFallDown
WeAllFallDown Jan. 21 at 7:38 PM
$SLN Anyone else find that the board actions were a bit strange, someone care to explain?
2 · Reply
LIGator
LIGator Jan. 20 at 12:59 PM
$SLN pretty heavy premarket activity today. Let’s see if we can get a little bounce.
0 · Reply
hitmongreen
hitmongreen Jan. 16 at 6:56 PM
$SLN someone say something smart!
1 · Reply
Market_Luther_Kang
Market_Luther_Kang Jan. 14 at 10:57 AM
$SLN The "digital smoke" is getting thick. 🕵️‍♂️ Just audited the IR server (q4cdn) and we’ve got a massive technical shift. The /2026/ directory just flipped from a 403 Forbidden to a 302 Redirect. Why this matters: A 302 redirect means the content is STAGED and LIVE on the backend, but they are temporarily routing traffic away until the exact "Go-Live" timestamp. Combine that with the new http://Schema.org "@type: Event" tags that just hit the header code for Jan 14th, and you realize this isn't just a slide deck update. You don't "embargo" a routine presentation. You embargo a Merger Announcement. Don't forget the Jan 6th Form 4s—the entire board (Ross, Hellums, etc.) converted their options to common shares 8 days ago. They cleaned the cap table for a reason. I think we see an announcement soon.
0 · Reply
LIGator
LIGator Jan. 12 at 7:28 PM
$SLN $GLSI What a great turnaround today for my two biggest micro cap stocks. 2026 should be a great year for both companies.
1 · Reply
Market_Luther_Kang
Market_Luther_Kang Jan. 11 at 1:36 AM
$SLN Theory Alert The administrative trail for Silence Therapeutics has shifted from routine partnership to a definitive buyout signature. It started on December 1 when AstraZeneca management met with Rothschild in London to lock the valuation models. Exactly fourteen days later the CEO was removed to install Iain Ross who is a veteran M&A specialist with a history of closing eight IPOs. The board then issued 90k shares to James Ede-Golightly on December 18 with a double trigger acceleration clause for immediate vesting upon a change of control. The final technical signal came on January 6 when a massive cluster of Form 4 filings hit the SEC to clean up board equity counts before the conversion to cash. Silence is now entirely missing from the J.P. Morgan schedule while AstraZeneca holds a Monday morning keynote. The stage is set for a merger announcement at 7 AM ET this Monday.
1 · Reply
Market_Luther_Kang
Market_Luther_Kang Jan. 9 at 12:41 AM
$SLN In the world of siRNA, there is a Holy Grail of chemistry: how to attach the targeting sugar (GalNAc) to the drug so it stays stable in the blood but releases perfectly inside the cell. • The Secret: Silence owns the patent on a specific "versatile linker chemistry" that is arguably the most efficient in the world. • The Trap: Alnylam and Arrowhead have their own linkers, but as the industry moves toward "extra-hepatic" (non-liver) delivery, they are finding that Silence’s linkers are often the only ones that work without causing toxicity or losing potency. • The Revenue Trigger: This is why Alnylam is already paying Silence a royalty on Onpattro sales in the EU. It wasn't a choice; it was a toll they had to pay to keep their drug on the market. Big Pharma would rather buy the Toll Booth (Silence) than pay the toll for the next 15 years.
0 · Reply
Market_Luther_Kang
Market_Luther_Kang Jan. 8 at 7:20 PM
$SLN back here now after taking a hit on the chin from IMRX. Cheapest SiRNA platform available for purchase with two very promising assets, cash runway to 2028, and an interim CEO brought in to sell. All the makings of a successful exit but I'll have to dig into things. Looking forward to seeing how it all plays out.
0 · Reply
LIGator
LIGator Dec. 31 at 7:59 PM
$SLN morons selling to lock in a tax loss. Under $6 is a great buy for a January recovery.
0 · Reply
PennyScam
PennyScam Dec. 29 at 5:38 PM
$SLN Great longterm investment. Love this arena. So good. Crazy K
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 9:48 PM
$SLN RSI: 33.90, MACD: -0.0811 Vol: 0.29, MA20: 6.45, MA50: 6.65 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ShoulderSurfing
ShoulderSurfing Dec. 26 at 1:49 PM
$SLN Leadership will be measured by consistency rather than by vision alone. Capital allocation choices will reveal true priorities. Missteps would reset expectations abruptly. Sentiment should follow consistency rather than noise.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 16 at 10:53 AM
$SLN Share Price: $6.61 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $0.77 – $0.95 Target Zone: $1.24 – $1.52 Potential Upside: 54% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply